Candel Therapeutics, Inc. (CADL) analyst actions
Rating and price-target actions on CADL in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CADL overview →
1 measured CADL analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Press release | +0.86% | -1.34% |
Keep exploring
More CADL: earnings → · SEC filings → · CADL overview →